Alembic Pharmaceuticals partners with Enthral.ai for learning and training management of its 9000+ learners
Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
This marks a meaningful step in the company's continued expansion in the region
A key milestone in this journey has been the introduction of TREAT Program, a first-of-its-kind clinical initiative introduced in India
Certification by TÜV SÜD Product Service GmbH reinforces the company's commitment to globally benchmarked standards in safety, quality, and performance
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
Subscribe To Our Newsletter & Stay Updated